Low-density lipoprotein-independent improvement of flow-mediated dilatation with atorvastatin: A meta-analysis and meta-regression of randomized controlled trials

Takagi, Hisato; Yamamoto, Hirotaka; Iwata, Kotaro; Goto, Shin-nosuke; Umemoto, Takuya

doi:10.1016/j.ijcard.2012.04.054

Cited by 9 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, different statins coupled with hypolipidemic diet have been tested in experimental murine and clinical models, documenting positive effects on endothelial function [ 118 ]. This is in line with the meta-analytical evidence that statin administration is able to improve FMD [ 119 ] while lowering blood concentrations of P-selectin, E-selectin, and ADMA [ 120 , 121 ].…”

Section: Therapeutic Targets For Endothelial Dysfunction In Hypertensionsupporting

confidence: 84%

Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension

Ambrosino

Bachetti

D’Anna

et al. 2022

JCDD

View full text Add to dashboard Cite

The endothelium is composed of a monolayer of endothelial cells, lining the interior surface of blood and lymphatic vessels. Endothelial cells display important homeostatic functions, since they are able to respond to humoral and hemodynamic stimuli. Thus, endothelial dysfunction has been proposed as a key and early pathogenic mechanism in many clinical conditions. Given the relevant repercussions on cardiovascular risk, the complex interplay between endothelial dysfunction and systemic arterial hypertension has been a matter of study in recent years. Numerous articles have been published on this issue, all of which contribute to providing an interesting insight into the molecular mechanisms of endothelial dysfunction in arterial hypertension and its role as a biomarker of inflammation, oxidative stress, and vascular disease. The prognostic and therapeutic implications of endothelial dysfunction have also been analyzed in this clinical setting, with interesting new findings and potential applications in clinical practice and future research. The aim of this review is to summarize the pathophysiology of the relationship between endothelial dysfunction and systemic arterial hypertension, with a focus on the personalized pharmacological and rehabilitation strategies targeting endothelial dysfunction while treating hypertension and cardiovascular comorbidities.

show abstract

Section: Therapeutic Targets For Endothelial Dysfunction In Hypertensionsupporting

confidence: 84%

Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension

Ambrosino

Bachetti

D’Anna

et al. 2022

JCDD

View full text Add to dashboard Cite

show abstract

“…Nevertheless, some previous clinical studies have reported on these beneficial effects on endothelial cell function [ 14 , 15 ]. It has also been reported that calculated FMD is a sensitive parameter that is easily confounded by many factors such as patients’ background (heart rate, sex, age, obesity and smoking) [ 33 ], conditions (air temperature, mental/physical stress) [ 34 – 36 ], and medications such as angiotensin II receptor blockers [ 37 ], statins [ 38 ] and some types of anti-hypoglycemic agents [ 18 , 39 ]. In this study, there were no significant differences in both groups for any of these confounding factors.…”

Section: Discussionmentioning

confidence: 99%

A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1)

et al. 2016

View full text Add to dashboard Cite

ObjectivesThe DPP-4 inhibitors are incretin-related drugs that improve hyperglycemia in a glucose-dependent manner and have been reported to exert favorable effects on atherosclerosis. However, it has not been fully elucidated whether DPP-4 inhibitors are able to improve endothelial function in patients with type 2 diabetes. Therefore, we investigated the efficacy of sitagliptin, a DPP-4 inhibitor, on endothelial function and glycemic metabolism compared with that of the sulfonylurea glimepiride.Materials and MethodsIn this multicenter, prospective, randomized parallel-group comparison study, 103 outpatients with type 2 diabetes (aged 59.9 ± 9.9 years with HbA1c levels of 7.5 ± 0.4%) with dietary cure only and/or current metformin treatment were enrolled and randomly assigned to receive sitagliptin or glimepiride therapy once daily for 26 weeks. Flow-mediated dilation (FMD), a comprehensive panel of hemodynamic parameters (Task Force® Monitor), and serum metabolic markers were assessed before and after the treatment.ResultsDuring the study period, no statistically significant change in %FMD was seen in both groups (sitagliptin, 5.6 to 5.6%; glimepiride, 5.6 to 6.0%). Secretory units of islets in transplantation, TNF-α, adiponectin and biological antioxidant potential significantly improved in the sitagliptin group, and superoxide dismutase also tended to improve in the sitagliptin group, while improvements in HbA1c levels were similar between groups. Cardiac index, blood pressure and most other metabolic parameters were not different.ConclusionsRegardless of glycemic improvement, early sitagliptin therapy did not affect endothelial function but may provide favorable effects on beta-cell function and on inflammatory and oxidative stress in patients with type 2 diabetes without advanced atherosclerosis.Trial RegistrationUMIN Clinical Trials Registry System UMIN 000004955

show abstract

“…In this trial, liraglutide reduced HbA1c levels from baseline similar to glargine treatment (-1.2% vs -0.7%, p = 0.14), but improvement in %FMD was not observed in either group. Calculated %FMD has been reported to be affected by many confounding factors, for example patients’ background (gender, age, obesity, heart rate and smoking) [ 22 ], conditions (air temperature, mental/physical stress) [ 23 – 25 ], medications such as angiotensin II receptor blockers [ 26 ], statins [ 27 ] and some anti-diabetic agents [ 16 , 28 ]. However, prevalence of these potential confounders was not different between groups and when adjusted for baseline %FMD, there remained no statistical difference between groups.…”

Section: Discussionmentioning

confidence: 99%

A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)

et al. 2015

View full text Add to dashboard Cite

ObjectivesGLP-1 improves hyperglycemia, and it has been reported to have favorable effects on atherosclerosis. However, it has not been fully elucidated whether GLP-1 is able to improve endothelial function in patients with type 2 diabetes. Therefore, we investigated the efficacy of the GLP-1 analogue, liraglutide on endothelial function and glycemic metabolism compared with insulin glargine therapy.Materials and MethodsIn this multicenter, prospective randomized parallel-group comparison study, 31 diabetic outpatients (aged 60.3 ± 10.3 years with HbA1c levels of 8.6 ± 0.8%) with current metformin and/or sulfonylurea treatment were enrolled and randomly assigned to receive liraglutide or glargine therapy once daily for 14 weeks. Flow mediated dilation (FMD), a comprehensive panel of hemodynamic parameters (Task Force Monitor), and serum metabolic markers were assessed before and after the treatment period.ResultsA greater reduction (worsening) in %FMD was observed in the glargine group, although this change was not statistically different from the liraglutide group (liraglutide; 5.7 to 5.4%, glargine 6.7 to 5.7%). The augmentation index, C-peptide index, derivatives of reactive oxygen metabolites and BMI were significantly improved in the liraglutide group. Central systolic blood pressure and NT-proBNP also tended to be improved in the liraglutide-treated group, while improvements in HbA1c levels were similar between groups. Cardiac index, blood pressure and most other metabolic parameters were not different.ConclusionsRegardless of glycemic improvement, early liraglutide therapy did not affect endothelial function but may provide favorable effects on beta-cell function and cardioprotection in type 2 diabetics without advanced atherosclerosis.Trial RegistrationUMIN Clinical Trials Registry System as trial ID UMIN000005331.

show abstract

Low-density lipoprotein-independent improvement of flow-mediated dilatation with atorvastatin: A meta-analysis and meta-regression of randomized controlled trials

Cited by 9 publications

References 42 publications

Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension

Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension

A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1)

A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)

Contact Info

Product

Resources

About